Assessment of juvenile pigs to serve as human pediatric surrogates for preclinical formulation pharmacokinetic testing

Wyatt J. Roth, Candice B. Kissinger, Robyn R. McCain, Bruce R. Cooper, Jeremy N. Marchant-Forde, Rachel Vreeman, Sophia Hannou, Gregory T. Knipp

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Pediatric drug development is hampered by biological, clinical, and formulation challenges associated with age-based populations. A primary cause for this lack of development is the inability to accurately predict ontogenic changes that affect pharmacokinetics (PK) in children using traditional preclinical animal models. In response to this issue, our laboratory has conducted a proof-of-concept study to investigate the potential utility of juvenile pigs to serve as surrogates for children during preclinical PK testing of selected rifampin dosage forms. Pigs were surgically modified with jugular vein catheters that were externalized in the dorsal scapular region and connected to an automated blood sampling system (PigTurn-Culex-L). Commercially available rifampin capsules were administered to both 20 and 40 kg pigs to determine relevant PK parameters. Orally disintegrating tablet formulations of rifampin were also developed and administered to 20 kg pigs. Plasma samples were prepared from whole blood by centrifugation and analyzed for rifampin content by liquid chromatography-tandem mass spectrometry. Porcine PK parameters were determined from the resultant plasma-concentration time profiles and contrasted with published rifampin PK data in human adults and children. Results indicated significant similarities in dose-normalized absorption and elimination parameters between pigs and humans. Moreover, ontogenic changes observed in porcine PK parameters were consistent with ontogenic changes reported for human PK. These results demonstrate the potential utility of the juvenile porcine model for predicting human pediatric PK for rifampin. Furthermore, utilization of juvenile pigs during formulation testing may provide an alternative approach to expedite reformulation efforts during pediatric drug development.

Original languageEnglish
Pages (from-to)763-774
Number of pages12
JournalAAPS Journal
Volume15
Issue number3
DOIs
StatePublished - Jul 2013

Fingerprint

Swine
Pharmacokinetics
Rifampin
Pediatrics
Culex
Jugular Veins
Dosage Forms
Tandem Mass Spectrometry
Centrifugation
Liquid Chromatography
Pharmaceutical Preparations
Tablets
Capsules
Catheters
Animal Models
Population

Keywords

  • ADME
  • pediatric
  • pharmacokinetics
  • porcine
  • rifampin

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Roth, W. J., Kissinger, C. B., McCain, R. R., Cooper, B. R., Marchant-Forde, J. N., Vreeman, R., ... Knipp, G. T. (2013). Assessment of juvenile pigs to serve as human pediatric surrogates for preclinical formulation pharmacokinetic testing. AAPS Journal, 15(3), 763-774. https://doi.org/10.1208/s12248-013-9482-6

Assessment of juvenile pigs to serve as human pediatric surrogates for preclinical formulation pharmacokinetic testing. / Roth, Wyatt J.; Kissinger, Candice B.; McCain, Robyn R.; Cooper, Bruce R.; Marchant-Forde, Jeremy N.; Vreeman, Rachel; Hannou, Sophia; Knipp, Gregory T.

In: AAPS Journal, Vol. 15, No. 3, 07.2013, p. 763-774.

Research output: Contribution to journalArticle

Roth, WJ, Kissinger, CB, McCain, RR, Cooper, BR, Marchant-Forde, JN, Vreeman, R, Hannou, S & Knipp, GT 2013, 'Assessment of juvenile pigs to serve as human pediatric surrogates for preclinical formulation pharmacokinetic testing', AAPS Journal, vol. 15, no. 3, pp. 763-774. https://doi.org/10.1208/s12248-013-9482-6
Roth, Wyatt J. ; Kissinger, Candice B. ; McCain, Robyn R. ; Cooper, Bruce R. ; Marchant-Forde, Jeremy N. ; Vreeman, Rachel ; Hannou, Sophia ; Knipp, Gregory T. / Assessment of juvenile pigs to serve as human pediatric surrogates for preclinical formulation pharmacokinetic testing. In: AAPS Journal. 2013 ; Vol. 15, No. 3. pp. 763-774.
@article{b44cdd07ca324630b4c1c06880603300,
title = "Assessment of juvenile pigs to serve as human pediatric surrogates for preclinical formulation pharmacokinetic testing",
abstract = "Pediatric drug development is hampered by biological, clinical, and formulation challenges associated with age-based populations. A primary cause for this lack of development is the inability to accurately predict ontogenic changes that affect pharmacokinetics (PK) in children using traditional preclinical animal models. In response to this issue, our laboratory has conducted a proof-of-concept study to investigate the potential utility of juvenile pigs to serve as surrogates for children during preclinical PK testing of selected rifampin dosage forms. Pigs were surgically modified with jugular vein catheters that were externalized in the dorsal scapular region and connected to an automated blood sampling system (PigTurn-Culex-L). Commercially available rifampin capsules were administered to both 20 and 40 kg pigs to determine relevant PK parameters. Orally disintegrating tablet formulations of rifampin were also developed and administered to 20 kg pigs. Plasma samples were prepared from whole blood by centrifugation and analyzed for rifampin content by liquid chromatography-tandem mass spectrometry. Porcine PK parameters were determined from the resultant plasma-concentration time profiles and contrasted with published rifampin PK data in human adults and children. Results indicated significant similarities in dose-normalized absorption and elimination parameters between pigs and humans. Moreover, ontogenic changes observed in porcine PK parameters were consistent with ontogenic changes reported for human PK. These results demonstrate the potential utility of the juvenile porcine model for predicting human pediatric PK for rifampin. Furthermore, utilization of juvenile pigs during formulation testing may provide an alternative approach to expedite reformulation efforts during pediatric drug development.",
keywords = "ADME, pediatric, pharmacokinetics, porcine, rifampin",
author = "Roth, {Wyatt J.} and Kissinger, {Candice B.} and McCain, {Robyn R.} and Cooper, {Bruce R.} and Marchant-Forde, {Jeremy N.} and Rachel Vreeman and Sophia Hannou and Knipp, {Gregory T.}",
year = "2013",
month = "7",
doi = "10.1208/s12248-013-9482-6",
language = "English",
volume = "15",
pages = "763--774",
journal = "AAPS Journal",
issn = "1550-7416",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Assessment of juvenile pigs to serve as human pediatric surrogates for preclinical formulation pharmacokinetic testing

AU - Roth, Wyatt J.

AU - Kissinger, Candice B.

AU - McCain, Robyn R.

AU - Cooper, Bruce R.

AU - Marchant-Forde, Jeremy N.

AU - Vreeman, Rachel

AU - Hannou, Sophia

AU - Knipp, Gregory T.

PY - 2013/7

Y1 - 2013/7

N2 - Pediatric drug development is hampered by biological, clinical, and formulation challenges associated with age-based populations. A primary cause for this lack of development is the inability to accurately predict ontogenic changes that affect pharmacokinetics (PK) in children using traditional preclinical animal models. In response to this issue, our laboratory has conducted a proof-of-concept study to investigate the potential utility of juvenile pigs to serve as surrogates for children during preclinical PK testing of selected rifampin dosage forms. Pigs were surgically modified with jugular vein catheters that were externalized in the dorsal scapular region and connected to an automated blood sampling system (PigTurn-Culex-L). Commercially available rifampin capsules were administered to both 20 and 40 kg pigs to determine relevant PK parameters. Orally disintegrating tablet formulations of rifampin were also developed and administered to 20 kg pigs. Plasma samples were prepared from whole blood by centrifugation and analyzed for rifampin content by liquid chromatography-tandem mass spectrometry. Porcine PK parameters were determined from the resultant plasma-concentration time profiles and contrasted with published rifampin PK data in human adults and children. Results indicated significant similarities in dose-normalized absorption and elimination parameters between pigs and humans. Moreover, ontogenic changes observed in porcine PK parameters were consistent with ontogenic changes reported for human PK. These results demonstrate the potential utility of the juvenile porcine model for predicting human pediatric PK for rifampin. Furthermore, utilization of juvenile pigs during formulation testing may provide an alternative approach to expedite reformulation efforts during pediatric drug development.

AB - Pediatric drug development is hampered by biological, clinical, and formulation challenges associated with age-based populations. A primary cause for this lack of development is the inability to accurately predict ontogenic changes that affect pharmacokinetics (PK) in children using traditional preclinical animal models. In response to this issue, our laboratory has conducted a proof-of-concept study to investigate the potential utility of juvenile pigs to serve as surrogates for children during preclinical PK testing of selected rifampin dosage forms. Pigs were surgically modified with jugular vein catheters that were externalized in the dorsal scapular region and connected to an automated blood sampling system (PigTurn-Culex-L). Commercially available rifampin capsules were administered to both 20 and 40 kg pigs to determine relevant PK parameters. Orally disintegrating tablet formulations of rifampin were also developed and administered to 20 kg pigs. Plasma samples were prepared from whole blood by centrifugation and analyzed for rifampin content by liquid chromatography-tandem mass spectrometry. Porcine PK parameters were determined from the resultant plasma-concentration time profiles and contrasted with published rifampin PK data in human adults and children. Results indicated significant similarities in dose-normalized absorption and elimination parameters between pigs and humans. Moreover, ontogenic changes observed in porcine PK parameters were consistent with ontogenic changes reported for human PK. These results demonstrate the potential utility of the juvenile porcine model for predicting human pediatric PK for rifampin. Furthermore, utilization of juvenile pigs during formulation testing may provide an alternative approach to expedite reformulation efforts during pediatric drug development.

KW - ADME

KW - pediatric

KW - pharmacokinetics

KW - porcine

KW - rifampin

UR - http://www.scopus.com/inward/record.url?scp=84879793564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879793564&partnerID=8YFLogxK

U2 - 10.1208/s12248-013-9482-6

DO - 10.1208/s12248-013-9482-6

M3 - Article

C2 - 23595360

AN - SCOPUS:84879793564

VL - 15

SP - 763

EP - 774

JO - AAPS Journal

JF - AAPS Journal

SN - 1550-7416

IS - 3

ER -